Q4 2025 Relmada Therapeutics Inc Earnings Call Transcript
Key Points
- Relmada Therapeutics Inc (RLMD) reported compelling 12-month efficacy data for their Phase 2 study of NDV-01, showing a high response rate and favorable safety profile.
- The company achieved FDA alignment for their planned Phase 3 rescue programs, which include two independent registrational pathways.
- Relmada completed a successful EUR 160 million private financing, providing capital through 2029 and supporting the completion of the planned Phase 3 program.
- The company strengthened its development team with the appointment of Dr. Raj Pruthi as Chief Medical Officer, Oncology, and established a scientific advisory board.
- Relmada plans to initiate a Phase 3 rescue program for NDV-01 in bladder cancer and a Phase 2 proof of concept trial for sepranolone in Prader-Willi syndrome, indicating a robust pipeline and future growth potential.
- The net loss for the three months ended December 31, 2025, was $19.9 million, an increase from the previous year's net loss of $18.7 million.
- General and administrative expenses increased by approximately $4.2 million compared to the previous year, driven by higher compensation costs.
- Research and development expenses decreased, primarily due to the completion of two Phase 3 trials, indicating potential challenges in maintaining R&D momentum.
- The company faces competition in the bladder cancer treatment space, which could impact enrollment cadence and market positioning.
- There are concerns about ensuring that patients in the second-line treatment pathway are truly second-line, as some may have received multiple prior therapies.
Good afternoon and welcome to the Relmada Therapeutics fourth-quarter and full-year 2025 earnings conference call. (Operator Instructions) As a reminder, this conference call is being recorded and will be available for replay on the Relmada website.
I would now like to turn the call over to Brian Ritchie from LifeSci Advisors. Please go ahead, Mr. Ritchie.
Good day everyone and thank you for joining us today. This afternoon, Relmada issued a press release providing a business update and outlining its financial results for the three months and year-ended December 30, 2025.
Please note that certain information discussed on the call today is covered under the Safe Harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
